Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer
Status:
RECRUITING
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
In recurrent advanced cervical cancer, patients were prone to drug resistance who have relapsed within prior platinum-based chemotherapy. However, immune checkpoint inhibitor's combination therapy has become a promising strategy for advanced cervical cancer. Epidermal Growth Factor Receptor (EGFR) is overexpressed in cervical cancer cells. Stereotactic radiotherapy (SBRT) can enhance the efficacy of immunotherapy.